

Scan W/RCE 09/03/09  
IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE

Serial No. : 10/525,986  
Applicants : Tadashi NAKAJIMA et al.  
Filed : February 25, 2005  
For : THERAPEUTIC AGENT FOR  
GLAUCOMA COMPRISING Rho  
KINASE INHIBITOR AND  
PROSTAGLANDIN  
Art Unit : 1612  
Examiner : Sean M. BASQUILL  
Docket No. : 05116/HG  
Confirm. No.: 5004  
Customer No.: 01933

EXPEDITED PROCEDURE  
REPLY UNDER 37 CFR 1.116  
TECHNOLOGY CENTER 1600

This paper is being submitted  
via EFS-Web on

July 10, 2009

In the event that this Paper  
is late filed, and the  
necessary petition for  
extension of time is  
not filed concurrently  
herewith, please consider  
this as a Petition for the  
requisite extension of time,  
and to the extent not already  
paid, authorization to charge  
the extension fee to Account  
No. 06-1378. In addition,  
authorization is hereby given  
to charge any fees for which  
payment has not been submitted,  
or to credit any overpayments,  
to Account No. 06-1378.

AMENDMENT UNDER 37 CFR 1.116

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

MAIL STOP AF

S I R :

This is in response to the Office Action mailed January 12,  
2009, the term for response to which is extended three months by  
a PETITION FOR EXTENSION OF TIME filed concomitantly herewith to  
expire on July 12, 2009. A Notice of Appeal is being filed  
concomitantly herewith. Please amend the above-identified  
application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which  
begins on page 5 of this paper.

Remarks begin on page 8 of this paper.